Aventis plasma-derived products
Labeling for Monoclate-P, Mononine, Gammar-P I.V., Albuminar-5, Albuminar-20 and Albuminar-25 has been revised to note that the plasma-derived products have undergone polymerase chain reaction testing for viruses. The new labeling states that "the plasma used in the manufacture of this product has been tested and found negative for HBV, HCV, and HIV-1, by an investigation test procedure referred to as nucleic acid testing (NAT) using polymerase chain reaction (PCR) technology"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth